A cannabinoid mechanism in relapse to cocaine seeking

Author:  ["Taco J. De Vries","Yavin Shaham","Judith R. Homberg","Hans Crombag","Karianne Schuurman","Jeanine Dieben","Louk J.M.J. Vanderschuren","Anton N.M. Schoffelmeer"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

Treatment of cocaine addiction is hampered by high rates of relapse even after prolonged drug abstinence. This relapse to compulsive cocaine use can be triggered by re-exposure to cocaine1, by re-exposure to stimuli previously associated with cocaine2 or by exposure to stress3. In laboratory rats, similar events reinstate cocaine seeking after prolonged withdrawal periods4,5,6, thus providing a model to study neuronal mechanisms underlying the relapse to cocaine. The endocannabinoid system has been implicated in a number of neuropsychiatric conditions, including drug addiction7,8. The active ingredient of marijuana, Δ9-tetrahydrocannabinol, activates the mesolimbic dopamine (DA) reward system9,10 and has rewarding effects in preclinical models of drug abuse8,11,12. We report here that the synthetic cannabinoid agonist, HU210 (ref. 13), provokes relapse to cocaine seeking after prolonged withdrawal periods. Furthermore, the selective CB1 receptor antagonist, SR141716A (ref. 14), attenuates relapse induced by re-exposure to cocaine-associated cues or cocaine itself, but not relapse induced by exposure to stress. These data reveal an important role of the cannabinoid system in the neuronal processes underlying relapse to cocaine seeking, and provide a rationale for the use of cannabinoid receptor antagonists for the prevention of relapse to cocaine use.

Cite this article

De Vries, T., Shaham, Y., Homberg, J. et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7, 1151–1154 (2001). https://doi.org/10.1038/nm1001-1151

View full text

>> Full Text:   A cannabinoid mechanism in relapse to cocaine seeking

Regulation of pancreatic β-cell growth and survival by the serine/threonine protein kinase Akt1/PKBα

Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling